Citations

Mayo Clinic

Clear

1175 citation(s) found for "Ha, Alex".

Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Yeatman, Timothy J. , Tibshirani, Robert , Williams, Richard T. , Hartman, Anne‐Renee , Seiden, Michael V., Liu, Minetta C. , Klein, Eric A. , Hubbell, Earl , Aravanis, Alexander M. , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Smith, David A. B.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12021-12021

10.1200/jco.2018.36.15_suppl.12021 Get It

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.
Venn, Oliver, Aravanis, Alex, Maddala, Tara, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Yeatman, Timothy J. , Seiden, Michael V., Oxnard, Geoffrey R. , Liu, Minetta C. , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José , Swanton, Charles , Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Zhang, Nan , Bolton, Kelly L.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12003-12003

10.1200/jco.2018.36.15_suppl.12003 Get It

A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Azad, Nilofer S. , Dy, Grace K. , Gallagher, Denise , Brennen, Caden, Cutler, David L. , Kramer, Douglas, Kwan, Rudolf, Fetterly, Gerald J., Adjei, Alex A. , Jimeno, Antonio , Wee, Wen , Lam, Elaine T. , Diamond, Jennifer R. , Opyrchal, Mateusz , Chan, Wing‐Kai

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2526-2526

10.1200/jco.2018.36.15_suppl.2526 Get It

Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience.
Robert, Nicholas J. , Northfelt, Donald W. , Jahanzeb, Mohammad , Wong, Shukmei , Hodge, K. Alex, Aldrich, Jessica, Craig, David W. , Wulfkuhle, Julia , Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David, Vocila, Linda, Dunetz, Bryant, Carpten, John D. , Petricoin, Emanuel F. , Anthony, Stephen P. , Pierobon, Mariaelena , Liotta, Lance A. , Gallagher, Rosa I.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1077-1077

10.1200/jco.2018.36.15_suppl.1077 Get It

Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?
Duma, Narjust , Yadav, Siddhartha , Vera-Aguilera, Jesús, Kottschade, Lisa A. , Adjei, Alex A. , Dronca, Roxana , Yadav, Siddhartha , Paludo, Jonas , Enninga, Elizabeth Ann L. , Dong, Haidong

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9547-9547

10.1200/jco.2018.36.15_suppl.9547 Get It

Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.
Adjei, Alex A. , Philip, Philip Agop, Mercadé, T. Macarulla, Walter, Annette O., Cupit, Lisa, Fields, Scott Z., Holynskyj, Ariadna, Bekaii‐Saab, Tanios , Berlin, Jordan D. , Liu, Rong

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS2607-TPS2607

10.1200/jco.2018.36.15_suppl.tps2607 Get It

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
Liu, Minetta C. , Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Smith, David A. , Curtis, Christina , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José, Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Couch, Fergus J. , Klein, Eric A.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2018.36.15_suppl.536 Get It

Temporal lobe contusions on computed tomography are associated with impaired 6-month functional recovery after mild traumatic brain injury: a TRACK-TBI study
Yue, John K. , Winkler, Ethan A. , Puffer, Ross C. , Deng, Hansen , Wagle, Sagar, Morrissey, Molly Rose, Rivera, Ernesto J. , Runyon, Sarah J., Vassar, Mary J. , Taylor, Sabrina R. , Cnossen, Maryse C. , Lingsma, Hester F. , Yuh, Esther L. , Schnyer, David M. , Puccio, Ava M. , Valadka, Alex B. , Okonkwo, David O. , Manley, Geoffrey T. , Investigators, the TRACK-TBI, Schnyer, David M , Phelps, Ryan , Mukherjee, Pratik

Neurological Research | September 3, 2018 | Volume: 40 | Issue: 11 | Pages: 972-981

10.1080/01616412.2018.1505416 | PMID 30175944 Get It

Age-dependent effects of thoracic and capillary blood volume distribution on pulmonary artery pressure and lung diffusing capacity
Coffman, Kirsten E. , Boeker, Matthew G., Carlson, Alex R. , Johnson, Bruce D.

Physiological Reports | September 2, 2018 | Volume: 6 | Issue: 17 | Pages: e13834

10.14814/phy2.13834 | PMID 30175463 Get It

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
Lou, Yanyan , Dholaria, Bhagirathbhai , Soyano, Aixa , Hodge, David O. , Cochuyt, Jordan J., Thomas, Mathew , Johnson, Margaret M. , Patel, Neal M. , Miller, Robert C. , Adjei, Alex A. , Hodge, David, Cochuyt, Jordan, Manochakian, Rami , Ko, Stephen J. , Ailawadhi, Sikander , Thomas, Mathew , Dholaria, Bhagirathbhai R , Soyano, Aixa , Ailawadhi, Sikander

Cancer Medicine | September 2, 2018 | Volume: 7 | Issue: 10 | Pages: 4932-4942

10.1002/cam4.1749 | PMID 30175515 Get It

Abstract Background Treatment of non‐small‐cell lung cancer (NSCLC) has been rapidly advancing over the last decade. Academic centers are considered equipped with better expertise. NSCLC outcome trends in novel therapeutic era and impact of initial treatment at academic centers have not been reported. Methods The National Cancer Database (NCDB) was used to identify NSCLC incident cases from 2004 to 2013. Overall survival (OS) was plotted by year of diagnosis and type of initial treatment center, accounting for several factors available in NCDB. Results A total of 1 150 722 NSCLC patients were included and separated by initial treatment center type (academic: 31.5%; nonacademic: 68.5%). Median follow‐up and OS for all patients were 11.8 months (range: 0‐133.6 months) and 13.1 months (95% CI: 13.08‐13.17), respectively. Median OS improved significantly for those diagnosed in 2010‐2013 (14.8 months [95% CI: 14.7‐14.9]) as compared to 2004‐2009 (12.4 months [95% CI: 12.3‐12.5]) ( P < 0.001). Treatment at academic centers was associated with improved OS (multivariate HR for OS = 0.929 [95% CI: 0.92‐0.94], P < 0.0010). Four‐year OS for academic and nonacademic cohorts was 28.5%% and 22.1%, respectively ( P < 0.001), and the difference was more pronounced in stage I to III NSCLC. Conclusion In this largest analysis, thus far, NSCLC survival has improved over time, and type of initial treatment center significantly influences survival. Identifying and removing barriers to obtaining initial treatment of NSCLC at academic medical centers could improve OS.